Resona Asset Management Co. Ltd. lowered its stake in Amgen Inc. (NASDAQ:AMGN – Free Report) by 1.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 162,470 shares of the medical research company’s stock after selling 1,681 shares during the period. Resona Asset Management Co. Ltd.’s holdings in Amgen were worth $68,559,000 at the end of the most recent quarter.
Several other institutional investors have also recently bought and sold shares of the stock. Wellington Altus USA Inc. lifted its stake in shares of Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 34 shares during the period. Quest 10 Wealth Builders Inc. lifted its position in Amgen by 220.0% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 80 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 55 shares during the period. Nvwm LLC lifted its position in Amgen by 412.5% during the 3rd quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 66 shares during the period. Security National Bank of Sioux City Iowa IA bought a new position in shares of Amgen in the 2nd quarter valued at about $36,000. Finally, PFS Partners LLC boosted its stake in shares of Amgen by 95.5% in the 3rd quarter. PFS Partners LLC now owns 86 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 42 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.
Amgen Stock Down 0.8%
NASDAQ:AMGN opened at $435.52 on Friday. Amgen Inc. has a 1 year low of $312.39 and a 1 year high of $483.99. The company has a current ratio of 1.48, a quick ratio of 1.20 and a debt-to-equity ratio of 3.60. The stock has a market cap of $235.58 billion, a price-to-earnings ratio of 25.26, a PEG ratio of 3.22 and a beta of 0.43. The stock has a 50-day moving average price of $430.44 and a two-hundred day moving average price of $383.81.
Amgen (NASDAQ:AMGN – Get Free Report) last released its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, topping analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. Amgen had a return on equity of 114.99% and a net margin of 24.14%. Amgen’s revenue was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm posted $5.64 earnings per share. As a group, equities analysts expect that Amgen Inc. will post 23.41 earnings per share for the current year.
Amgen Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be given a $2.52 dividend. The ex-dividend date is Friday, November 20th. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s payout ratio is currently 58.47%.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on AMGN shares. Freedom Broker downgraded shares of Amgen from a “buy” rating to a “hold” rating and boosted their price target for the stock from $450.00 to $470.00 in a research note on Friday, November 6th. BMO Capital Markets reduced their price objective on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a research note on Monday, October 12th. Scotiabank lifted their target price on shares of Amgen from $500.00 to $530.00 and gave the stock a “sector outperform” rating in a report on Wednesday, November 4th. TD Cowen upped their target price on shares of Amgen from $452.00 to $531.00 and gave the company a “buy” rating in a research report on Wednesday, November 4th. Finally, Weiss Ratings upgraded shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 8th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $428.62.
Get Our Latest Report on Amgen
Amgen Profile
Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.
Further Reading
- Five stocks we like better than Amgen
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.
